ZUEINO Drug Patent Profile
Which patents cover Zueino, and what generic alternatives are available?
Zueino is a drug marketed by Adventapharma and is included in one NDA.
The generic ingredient in ZUEINO is diclofenac sodium. There is one drug master file entry for this compound. One hundred and twenty-three suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zueino
A generic version of ZUEINO was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26th, 1996.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ZUEINO?
- What are the global sales for ZUEINO?
- What is Average Wholesale Price for ZUEINO?
Summary for ZUEINO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | ZUEINO at DailyMed |
US Patents and Regulatory Information for ZUEINO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adventapharma | ZUEINO | diclofenac sodium | SOLUTION;INTRAVENOUS | 218379-001 | Sep 25, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

